Sabine Hazan, MD

As a specialist in gastroenterology, internal medicine, and hepatology, Dr. Hazan has used her medical expertise in many regards over the last two decades. As the founder & CEO of Progenabiome, a genetic sequencing research laboratory, she leads 35+ studies investigating the role of the gut flora in various diseases (see current list here). Dr. Hazan is also the CEO of Ventura Clinical Trials, where she has 20+ years experience leading clinical trials for cutting-edge research on various medical issues. Since March 2020, she has been at the forefront of COVID-19 research, leading ongoing FDA-approved clinical trials for treatment and prophylaxis (details here). Through their study exploring the role of the gut flora in COVID-19, Progenabiome became the first lab worldwide to detect SARS-CoV-2 from Patient Fecal Samples by Whole Genome Sequencing. See data published in Gut Pathogens and the lab that identified Bifidobacteria as a key lost microbes in severe COVID patients.